Market development has moved decisively upstream in life sciences organisations. In our work across therapy areas and regions, it is no longer an optional discrete phase just before approval, but a critical enabler of early commercialisation and launch success.
When done well, market development shapes system readiness: aligning pathways, funding, stakeholders and capabilities so that innovation can be introduced at pace and sustained within real healthcare environments. This has become essential as launches increasingly take place in pressured systems, with policies still evolving to cope with the evaluation of new technologies, complex patient journeys, and therapy areas that require meaningful behaviour change across the whole care continuum from day one.
Health systems are under sustained strain, while scientific progress, particularly in immunology, chronic inflammatory disease, oncology and rare disease continues to accelerate. This creates a widening gap between what innovation makes possible and what systems are structurally capable of delivering. Early market development has evolved to close that gap, not through education alone, but through deliberate shaping of the ecosystem into which products launch, uniting stakeholders around a common goal of serving patients.
From early education to early system shaping
Education remains foundational, but awareness alone rarely unlocks successful early uptake. In pre-launch and peri-launch settings, the barriers that matter most are often embedded in the system itself: delayed diagnosis, fragmented referral routes, misaligned incentives and uneven capability across care settings.
In early commercialisation programmes, progress accelerates when organisations take an explicit ecosystem view. Bringing policymakers, clinicians, nurses, patient organisations, and industry partners into shared problem-solving conversations shifts the focus from “launch readiness” to system readiness.
AI is increasingly supporting this work by synthesising policy landscapes, surfacing patterns across stakeholder input and identifying where priorities align or conflict. Used well, this accelerates early strategic alignment and helps teams focus investment where it will have the greatest downstream impact at launch.
Patient journeys as launch decision tools
Patient journeys have taken on a more strategic role in early market development. Rather than static maps, they are now used as decision frameworks for launch planning.
Starting from a clean slate, teams explore the lived experience of patients and layer in HCP, payer and caregiver perspectives. AI-enabled analysis of qualitative and quantitative inputs helps identify where delays, drop-offs and behavioural bottlenecks will directly affect early uptake and persistence.
Over time, these journeys become a shared reference point for launch decisions:
- Where to prioritise diagnostic initiatives pre-launch
- Which pathway interventions are critical in the first 12–24 months
- How to sequence investment across markets and care settings
This creates stronger cross-functional alignment and reduces duplication, enabling organisations to move into launch with greater confidence and coherence.
Infrastructure as a pre-launch growth lever
Across many therapy areas, early commercial success is increasingly determined by infrastructure. Diagnostics, referral routes, and specialist capacity often determine whether patients receive treatment at all.
In chronic and immune-mediated diseases, market development efforts before launch are therefore focused on building system capability, not simply preparing messages. AI is supporting this by comparing market archetypes, identifying success patterns in early‑adopting countries and modelling how those conditions can be adapted elsewhere without losing sensitivity to local context.
This approach allows organisations to scale proven pre-launch interventions more efficiently, creating a foundation that supports not just a single launch, but portfolio growth over time.
Ways of working that match launch reality
The pace and uncertainty of modern launches have also reshaped how early market development teams work. In the most effective programmes, momentum comes from rapid alignment and iterative decision making, rather than exhaustive upfront planning.
AI increasingly supports scenario testing, trade-off exploration, and cross-functional synthesis, enabling earlier global‑local alignment and faster prioritisation. When combined with clear governance and shared strategic intent, this reduces launch risk and shortens decision cycles in complex environments.
Co-creation remains central. Brand, medical and access teams are integrated earlier, and external stakeholders are engaged where this directly contributes to system readiness rather than incremental activity.
A discipline designed for early impact
Market development in 2026 reflects a discipline shaped by practice in some of the most complex launches pharma has faced. At its best, it is patient-centred, system-aware and technologically enabled without being technology-led.
When applied early in the lifecycle, market development strengthens launch readiness, accelerates adoption and supports sustainable growth by ensuring innovation lands in systems that are prepared to deliver it at scale.
Contact us
